| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.02. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.02.2026 | 936 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.02.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.02.2026ISIN NameAU0000234676 ENRG... ► Artikel lesen | |
| 02.02. | Aquaporin A/S - Removal from trading on Nasdaq Copenhagen | 551 | GlobeNewswire | Aquaporin A/S (the company) will be removed from trading on Nasdaq Copenhagen due to the company having been declared bankrupt.
Trading in the company's shares has been suspended since 30 January... ► Artikel lesen | |
| 02.02. | Aquaporin A/S: Bankruptcy order issued for Aquaporin A/S | 381 | GlobeNewswire (Europe) | Company announcement
No. 05/2026Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694Kongens Lyngby, Denmark, February 2, 2026 - The Bankruptcy Court... ► Artikel lesen | |
| 30.01. | XFRA 00B: AUSSETZUNG/SUSPENSION | 286 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAQUAPORIN A/S DK... ► Artikel lesen | |
| 30.01. | Aquaporin A/S: Aquaporin announces withdrawal of its offering and resolves to initiate insolvency proceedings | 829 | PR Newswire | Company announcement No. 04/2026 Inside informationAquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694KONGENS LYNGBY, Denmark, Jan. 30, 2026... ► Artikel lesen | |
| 30.01. | Suspension of Trading in Aquaporin A/S at XCSE | 268 | GlobeNewswire | 2026-01-30T07:41:57Z
Suspension
At Trading Venue XCSE
Due to Technical Or
Administrative
Ongoing: True
Comments: We refer to company announcement No. 04
2026 disclosed by Aquaporin on January 30... ► Artikel lesen | |
| 26.01. | Aquaporin A/S: Aquaporin further postpones final results of rights issue due to current investor dialogues and uncertainty of completion | 288 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT... ► Artikel lesen | |
| AQUAPORIN Aktie jetzt für 0€ handeln | |||||
| 23.01. | Aquaporin A/S - Observation status | 292 | GlobeNewswire | Nasdaq Copenhagen has today given the below observation status:
ISIN NAME:
DK0061555109 AQUAPORIN
The company is given observation status because the company... ► Artikel lesen | |
| 23.01. | Aquaporin A/S: Aquaporin postpones final results of rights issue due to uncertainty of completion and its ability to remain a going concern | 279 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT... ► Artikel lesen | |
| 02.01. | Aquaporin A/S: Last day of trading in shares with pre-emptive rights in connection with rights issue | 552 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| 02.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.01.2026 | 619 | Xetra Newsboard | Das Instrument 00B DK0061555109 AQUAPORIN A/S DK 1 EQUITY wird cum Kapitalmassnahme gehandelt am 02.01.2026 und ex Kapitalmassnahme am 05.01.2026 The instrument 00B DK0061555109 AQUAPORIN A/S DK 1 EQUITY... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S - rights issue, admission to trading and official listing of subscription rights | 383 | GlobeNewswire | Subscription rights in Aquaporin A/S will be admitted to trading and official listing on Nasdaq Copenhagen as of 5 January 2026. As of the same date, ISIN DK0061555109 (AQP) will be traded excl.... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin initiates rights issue | 508 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin updates on strategic review and sets mid-and long-term financial targets | 682 | PR Newswire | Company announcementNo. 21/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 01.12.25 | Business transacted at the extraordinary general meeting of Aquaporin A/S | 456 | PR Newswire | Company announcementNo. 20/2025Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany reg. no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 1, 2025 /PRNewswire/ -- Aquaporin A/S... ► Artikel lesen | |
| 01.12.25 | Aquaporin A/S: Business transacted at the extraordinary general meeting of Aquaporin A/S | 269 | GlobeNewswire (Europe) | Company announcement
No. 20/2025
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company reg. no.: DK28315694
Kongens Lyngby, Denmark, December 1, 2025 - Aquaporin A/S ("Aquaporin"... ► Artikel lesen | |
| 13.11.25 | Aquaporin A/S: Aquaporin Q3 2025 Trading Statement | 365 | PR Newswire | Company announcement
No. 19/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11.25 | Aquaporin A/S: Notice to convene an extraordinary general meeting | 546 | PR Newswire | Company announcement
No. 18/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11.25 | Aquaporin A/S: Update on strategic review and intention to strengthen financial position | 492 | PR Newswire | Company announcement
No. 17/2025Inside information
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS... ► Artikel lesen | |
| 21.08.25 | Aquaporin A/S: Aquaporin announces results for first half 2025 | 473 | PR Newswire | Company announcement No. 16/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngby aquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, Aug. 21, 2025 /PRNewswire/... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,19 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,300 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,12 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 18,810 | -0,05 % | Erasca closes $632.5 million public stock offering | ||
| TARSUS PHARMACEUTICALS | 56,33 | +0,14 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,455 | +0,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,310 | -0,08 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,765 | -0,03 % | BMO initiates Trevi Therapeutics stock at Outperform, $36 target | ||
| HEMAB THERAPEUTICS | 49,390 | 0,00 % | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | ||
| KYMERA THERAPEUTICS | 111,11 | +0,04 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| QIAGEN | 36,020 | +0,15 % | Qiagen: KI-Kooperationen und Digital-PCR wecken Übernahmeinteresse | ||
| PRAXIS PRECISION MEDICINES | 304,26 | -0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| IMMIX BIOPHARMA | 8,800 | 0,00 % | Kehoe Law Firm, P.C.: Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims | Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma")... ► Artikel lesen | |
| VOR BIOPHARMA | 17,450 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,230 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen |